Glucuronate-modified, long-circulating liposomes for the delivery of anticancer agents

Methods in Enzymology

Volumn 391, Issue SPEC. ISS., 2005, Pages 145-162

  Oku, Naoto ^a   Namba, Yukihiro ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; GLUCURONIC ACID; LIPOSOME;

CANCER THERAPY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; ENCAPSULATION; HEMOLYSIS; MACROPHAGE; NONHUMAN; OPSONIZATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW;

EID: 13844253696     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(05)91008-2     Document Type: Article

References (38)

1. Allen T.M., Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett. 223:1987;42-46
2. Allen T.M., Hansen C., Martin F., Redeman C., Yau-Yong A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta. 1066:1991;29-36
3. Blume G., Cevc G. Liposomes for the sustained drug release in vivo. Biochim. Biophys. Acta. 1029:1990;91-97
4. Bradley A.J., Brooks D.E., Norris- Jones R., Devine D.V. C1q binding to liposomes is surface charge dependent and is inhibited by peptides consisting of residues 14-26 of the human C1qA chain in a sequence independent manner. Biochim. Biophys. Acta. 1418:1999;19-30
5. Cabanes A., Briggs K.E., Gokhale P.C., Treat J.A., Rahman A. Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int. J. Oncol. 12:1998;1035-1040
6. Chonn A., Semple S.C., Cullis P.R. Separation of large unilamellar liposomes from blood components by a spin column procedure: Towards identifying plasma proteins which mediate liposome clearance in vivo. Biochim. Biophys. Acta. 1070:1991;215-222
7. Colbern G.T., Dykes D.J., Engbers C., Musterer R., Hiller A., Pegg E., Saville R., Weng S., Luzzio M., Uster P., Amantea M., Working P.K. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: Pharmacokinetics and antitumor activity in HT29 colon tumor xenografts. Clin. Cancer Res. 4:1998;3077-3082
8. Derksen J.T.P., Morselt H.W.M., Scherphof G.L. Uptake and processing of immunoglobulin-coated liposomes by subpopulations of rat liver macrophages. Biochim. Biophys. Acta. 971:1988;127-136
9. Doi K., Oku N., Toyota T., Shuto S., Sakai A., Ito H., Okada S. Therapeutic effect of reticuloendothelial system (RES)-avoiding liposomes containing a phospholipid analogue of 5-fluorouracil, dipalmitoylphosphatidylfluorouridine, in Meth A sarcoma-bearing mice. Biol. Pharm. Bull. 17:1994;1414-1416
10. Embree L., Gelmon K., Tolcher A., Hudon N., Heggie J., Dedhar C., Logan P., Bally M.B., Mayer L.D. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother. Pharmacol. 41:1998;347-352
11. Gabizon A., Goren D., Cohen R., Barenholz Y. Development of liposomal anthracyclines: from basics to clinical applications. J. Control Release. 53:1998;275-279
12. Harashima H., Sakarta K., Funato K., Kiwada H. Enhanced hepatic uptake of liposomes through complement activation depend on the size of liposomes. Pharm. Res. 11:1994;402-406
13. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268:1990;235-237
14. Krishna R., Mayer L.D. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Cancer Res. 57:1997;5246-5253
15. Mayer L.D., Tai L.C.L., Bally M.B., Mitilenes G.N., Ginsberg R.S., Cullis P.R. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim. Biophys. Acta. 1025:1990;143-151
16. Namba Y., Oku N., Ito F., Sakakibara T., Okada S. Liposomal modification with uronate, which endows liposomes with long circulation in vivo. Reduces the uptake of J774 cells in vitro. Life Sci. 50:1992;1773-1779
17. Oku N. Anticancer therapy using glucuronate modified long-circulating liposomes. Adv. Drug Delivery Rev. 40:1999;63-73
18. Oku N., Namba Y. Long-circulating liposomes. Crit. Rev. Ther. Drug Carrier Syst. 11:1994;231-270
19. Oku N., Namba Y., Okada S. Tumor accumulation of novel RES-avoiding liposomes. Biochim. Biophys. Acta. 1126:1992;255-260
20. Oku N., Doi K., Namba Y., Okada S. Therapeutic effect of adriamycin encapsulated in long-circulating liposomes on Meth-A-sarcoma-bearing mice. Int. J. Cancer. 58:1994;415-419
21. Oku N., Tokudome Y., Tsukada H., Okada S. Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography Biochim. Biophys. Acta. 1238:1995;86-90
22. Oku N., Tokudome Y., Namba Y., Saito N., Endo M., Hasagawa Y., Kawai M., Tsukada H., Okada S. Effect of serum protein binding on real-time trafficking of liposomes with different charges analyzed by positron emission tomography. Biochim. Biophys. Acta. 1280:1996a;149-154
23. Oku N., Tokudome Y., Tsukada H., Kosugi T., Namba Y., Okada S. In vivo trafficking of long-circulating liposomes in tumour-bearing mice determined by positron emission tomography. Biopharm. Drug Dispos. 17:1996b;435-441
24. Oku N., Tokudome Y., Asai T., Tsukada H. Evaluation of drug targeting strategies and liposomal trafficking. Curr. Pharm. Des. 6:2000;1669-1691
25. Sadzuka Y., Hirota S. Does the amount of an antitumor agent entrapped in liposomes influence its tissue distribution and cell uptake? Cancer Lett. 131:1998;163-170
26. Sadzuka Y., Hirotsu S., Hirotu S. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11. Cancer Lett. 127:1998;99-106
27. Scialli A.R., Waterhouse T.B., Desesso J.M., Rahman A., Goeringer G.C. Protective effect of liposome encapsulation on paclitaxel developmental toxicity in the rat. Teratology. 56:1997;305-310
28. Symon Z., Peyser A., Tzemach D., Lyass O., Sucher E., Shezen E., Gabizon A. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer. 86:1999;72-78
29. Tokudome Y., Oku N., Doi K., Namba Y., Okada S. Antitumor activity of vincristine encapsulated in glucuronide-modified long-circulating liposomes in mice bearing Meth A sarcoma. Biochim. Biophys. Acta. 1279:1996;70-74
30. Vaage J., Donovan D., Wipff E., Abra R., Colbern G., Uster P., Working P. Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes. Int. J. Cancer. 80:1999;134-137
31. Vail D.M., Chun R., Thamm D.H., Garrett L.D., Cooley A.J., Obradovich J.E. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: A randomized, double-blind clinical trial using a canine model. Clin. Cancer Res. 4:1998;1567-1571
32. Valero V., Buzdar A.U., Theriault R.L., Azarnia N., Fonseca G.A., Willey J., Ewer M., Walters R.S., Mackay B., Podoloff D., Booser D., Lee L.W., Hortobagyi G.N. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J. Clin. Oncol. 17:1999;1425-1434
33. van Borssum Waalkes M., Goris H., Dontje B.H., Schwendener R.A., Scherphof G., Nijhof W. Toxicity of liposomal 3′-5′-O-dipalmitoyl-5- fluoro-2′-deoxyuridine in mice. Anticancer Drug Des. 13:1998;291-305
34. Verdonck L.F., Lokhorst H.M., Roovers D.J., van Heugten H.G. Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: Implications for liposome-encapsulated daunorubicin. Leuk. Res. 22:1998;249-256
35. Webb M.S., Saxon D., Wong F.M., Lim H.J., Wang Z., Bally M.B., Choi L.S., Cullis P.R., Mayer L.D. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): Effects on the pharmacokinetics of liposomal vincristine. Biochim. Biophys. Acta. 1372:1998;272-282
36. Working P.K., Newman M.S., Sullivan T., Brunner M., Podell M., Sahenk Z., Turner N. Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys. Toxicol. Sci. 46:1998;155-165
37. Zou Y., Priebe W., Stephens L.C., Perez-Soler R. Preclinical toxicity of liposome-incorporated annamycin: Selective bone marrow toxicity with lack of cardiotoxicity. Clin. Cancer Res. 1:1995;1369-1374
38. Zucchetti M., Boiardi A., Silvani A., Parisi I., Piccolrovazzi S., D'Incalci M. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin. Cancer Chemother. Pharmacol. 44:1999;173-176